

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

*Sub D* 1. (Currently amended) A method of treatment of solid tumors in a human in need of ~~such~~ said treatment, which comprises administering a therapeutically effective amount of one or more arsenic compounds, or a prodrug of one or more of said arsenic compounds, to said human, wherein said solid tumor is a tumor of the ~~breast, colon, ovary, kidney, central nervous system, bladder, prostate or lung.~~

2. (Previously amended) The method of claim 1, wherein said solid tumor is a metastatic tumor.

3. canceled

4. canceled

5. canceled

6. canceled

7. canceled

8. canceled

9. (Previously amended) The method of claim 4 wherein said tumor is a tumor of the central nervous system selected from the group consisting of neuroblastoma, retinoblastoma, glioblastoma and oligodentroglioma.

10. (Currently amended) The method of claim 1, or 2 ~~or 3~~ wherein said arsenic compound is an ionic aqueous solution of arsenic.

11. (Currently amended) The method of claim 1, or 2 ~~or 3~~ wherein said arsenic compound is selected from the group consisting of arsenic trioxide and Fowler's solution.

12. (Currently amended) The method of claim 1, ~~or 2 or 3~~ wherein the total daily amount administered is from about 10 µg to about 200 mg.
13. canceled
14. (Previously amended) The method of claim 1, in which said other therapeutic agent is a chemotherapeutic agent or radiotherapeutic agent.
15. (Previously amended) The method of claims 1 or 2, in which said administration is made parenterally, topically, dermally, directly into the tumor or orally.
16. (Previously amended) The method of claim 1, in which said other therapeutic agent is selected from the group consisting of etoposide, cisplatin, carboplatin, estramustine phosphate, vinblastine, methotrexate, hydroxyurea, cyclophosphamide, doxorubicin, 5-fluorouracil, taxol, diethylstilbestrol, VM-26 (vumon), BCNU, all-trans retinoic acid, procarbazine, cytokines, and therapeutic vaccines.
17. (Previously amended) The method of claim 1 or 2, in which said administration is made via an implantation device.
18. canceled
19. canceled
20. canceled
21. (Previously added) The method of claim 1, wherein arsenic trioxide is administered intravenously in a total daily dose of from 0.5 mg to 150 mg.
22. (Currently amended) The method of claim ~~2~~ 1, wherein arsenic trioxide is administered intravenously in a total daily dose of from 0.5 mg to 150 mg.

23. (Currently amended) The method of claim ~~3~~ 1 wherein arsenic trioxide is administered intravenously in a total daily dose of from 0.5 mg to 150 mg.

24. (Currently amended) The method of claim 1; or 2 ~~or 3~~, wherein the arsenic compound is an arsenic halide.

25. (Currently amended) The method of claim 1; or 2 ~~or 3~~, wherein the arsenic compound is an arsenic sulfide.

26. (Currently amended) The method of claim 1; or 2 ~~or 3~~, wherein the arsenic compound is an organic compound.

27. (Currently amended) The method of claim 1; or 2 ~~or 3~~, wherein the arsenic compound is administered as a prodrug.

28. (Currently amended) The method of claim 1; or 2 ~~or 3~~, wherein the arsenic compound is administered orally.

29. (Currently amended) The method of claim 1; or 2 ~~or 3~~, wherein the arsenic compound is administered as a pill or tablet.